Cargando…

[(18)F]FDG Positron Emission Tomography for Initial Staging and Healing Assessment at the End of Therapy in Lymph Nodes and Bone Tuberculosis

Objective: In extra-pulmonary tuberculosis, therapeutic management is difficult in the absence of reliable tool to affirm healing at the end of treatment. In this prospective multicenter study, we evaluated [(18)F]FDG-PET for this purpose. Methods: Forty-two patients out of 55 included patients coul...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarda-Mantel, Laure, Kaoutar, Jidar, Alfaiate, Toni, Lopes, Amanda, Paycha, Frédéric, Benali, Khadija, Mikail, Nidaa, Soussan, Michael, Lemarignier, Charles, Méchaï, Frédéric, Nagat, Sophie Le, Montravers, Françoise, Deradji, Ouda, Durand, Emmanuel, Goulenok, Tiphaine, Ponscarme, Diane, Yéni, Patrick, Laouénan, Cédric, Rioux, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416085/
https://www.ncbi.nlm.nih.gov/pubmed/34485345
http://dx.doi.org/10.3389/fmed.2021.715115
_version_ 1783748104005091328
author Sarda-Mantel, Laure
Kaoutar, Jidar
Alfaiate, Toni
Lopes, Amanda
Paycha, Frédéric
Benali, Khadija
Mikail, Nidaa
Soussan, Michael
Lemarignier, Charles
Méchaï, Frédéric
Nagat, Sophie Le
Montravers, Françoise
Deradji, Ouda
Durand, Emmanuel
Goulenok, Tiphaine
Ponscarme, Diane
Yéni, Patrick
Laouénan, Cédric
Rioux, Christophe
author_facet Sarda-Mantel, Laure
Kaoutar, Jidar
Alfaiate, Toni
Lopes, Amanda
Paycha, Frédéric
Benali, Khadija
Mikail, Nidaa
Soussan, Michael
Lemarignier, Charles
Méchaï, Frédéric
Nagat, Sophie Le
Montravers, Françoise
Deradji, Ouda
Durand, Emmanuel
Goulenok, Tiphaine
Ponscarme, Diane
Yéni, Patrick
Laouénan, Cédric
Rioux, Christophe
author_sort Sarda-Mantel, Laure
collection PubMed
description Objective: In extra-pulmonary tuberculosis, therapeutic management is difficult in the absence of reliable tool to affirm healing at the end of treatment. In this prospective multicenter study, we evaluated [(18)F]FDG-PET for this purpose. Methods: Forty-two patients out of 55 included patients could be analyzed. Additionally to usual biological, histological and morphological explorations, [(18)F]FDG-PET was performed at diagnosis (PET1), at the end of treatment (PET2), indeed 6 months later. Then patients were followed until 12 months after end of prescribed treatment. Results: PET1 was positive in 97.6% of patients and discovered unknown injured sites in 52.7% of cases. PET2 was positive in 83.3% of uncured patients, and in 82.3% of cured patients. The sum and mean value of SUV(max) measured in PET/CT lesions decreased between PET1 and PET2 in all patients. Mean value of SUV(max) (MSUV) and sum value of SUVmax on PET2 showed the highest AUC on ROC curves for the diagnosis of healing at the end of prescribed treatment; MSUV 3.5 on PET2 had a sensitivity of 76.5% and a specificity of 80.0% to affirm healing at the end of prescribed treatment. Conclusions: [(18)F]FDG-PET/CT was useful at diagnosis, discovering unknown lesions in 52.7% of cases. MSUV on PET2 was the best criteria to affirm healing at the end of prescribed treatment.
format Online
Article
Text
id pubmed-8416085
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84160852021-09-04 [(18)F]FDG Positron Emission Tomography for Initial Staging and Healing Assessment at the End of Therapy in Lymph Nodes and Bone Tuberculosis Sarda-Mantel, Laure Kaoutar, Jidar Alfaiate, Toni Lopes, Amanda Paycha, Frédéric Benali, Khadija Mikail, Nidaa Soussan, Michael Lemarignier, Charles Méchaï, Frédéric Nagat, Sophie Le Montravers, Françoise Deradji, Ouda Durand, Emmanuel Goulenok, Tiphaine Ponscarme, Diane Yéni, Patrick Laouénan, Cédric Rioux, Christophe Front Med (Lausanne) Medicine Objective: In extra-pulmonary tuberculosis, therapeutic management is difficult in the absence of reliable tool to affirm healing at the end of treatment. In this prospective multicenter study, we evaluated [(18)F]FDG-PET for this purpose. Methods: Forty-two patients out of 55 included patients could be analyzed. Additionally to usual biological, histological and morphological explorations, [(18)F]FDG-PET was performed at diagnosis (PET1), at the end of treatment (PET2), indeed 6 months later. Then patients were followed until 12 months after end of prescribed treatment. Results: PET1 was positive in 97.6% of patients and discovered unknown injured sites in 52.7% of cases. PET2 was positive in 83.3% of uncured patients, and in 82.3% of cured patients. The sum and mean value of SUV(max) measured in PET/CT lesions decreased between PET1 and PET2 in all patients. Mean value of SUV(max) (MSUV) and sum value of SUVmax on PET2 showed the highest AUC on ROC curves for the diagnosis of healing at the end of prescribed treatment; MSUV 3.5 on PET2 had a sensitivity of 76.5% and a specificity of 80.0% to affirm healing at the end of prescribed treatment. Conclusions: [(18)F]FDG-PET/CT was useful at diagnosis, discovering unknown lesions in 52.7% of cases. MSUV on PET2 was the best criteria to affirm healing at the end of prescribed treatment. Frontiers Media S.A. 2021-08-17 /pmc/articles/PMC8416085/ /pubmed/34485345 http://dx.doi.org/10.3389/fmed.2021.715115 Text en Copyright © 2021 Sarda-Mantel, Kaoutar, Alfaiate, Lopes, Paycha, Benali, Mikail, Soussan, Lemarignier, Méchaï, Nagat, Montravers, Deradji, Durand, Goulenok, Ponscarme, Yéni, Laouénan and Rioux. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Sarda-Mantel, Laure
Kaoutar, Jidar
Alfaiate, Toni
Lopes, Amanda
Paycha, Frédéric
Benali, Khadija
Mikail, Nidaa
Soussan, Michael
Lemarignier, Charles
Méchaï, Frédéric
Nagat, Sophie Le
Montravers, Françoise
Deradji, Ouda
Durand, Emmanuel
Goulenok, Tiphaine
Ponscarme, Diane
Yéni, Patrick
Laouénan, Cédric
Rioux, Christophe
[(18)F]FDG Positron Emission Tomography for Initial Staging and Healing Assessment at the End of Therapy in Lymph Nodes and Bone Tuberculosis
title [(18)F]FDG Positron Emission Tomography for Initial Staging and Healing Assessment at the End of Therapy in Lymph Nodes and Bone Tuberculosis
title_full [(18)F]FDG Positron Emission Tomography for Initial Staging and Healing Assessment at the End of Therapy in Lymph Nodes and Bone Tuberculosis
title_fullStr [(18)F]FDG Positron Emission Tomography for Initial Staging and Healing Assessment at the End of Therapy in Lymph Nodes and Bone Tuberculosis
title_full_unstemmed [(18)F]FDG Positron Emission Tomography for Initial Staging and Healing Assessment at the End of Therapy in Lymph Nodes and Bone Tuberculosis
title_short [(18)F]FDG Positron Emission Tomography for Initial Staging and Healing Assessment at the End of Therapy in Lymph Nodes and Bone Tuberculosis
title_sort [(18)f]fdg positron emission tomography for initial staging and healing assessment at the end of therapy in lymph nodes and bone tuberculosis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416085/
https://www.ncbi.nlm.nih.gov/pubmed/34485345
http://dx.doi.org/10.3389/fmed.2021.715115
work_keys_str_mv AT sardamantellaure 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT kaoutarjidar 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT alfaiatetoni 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT lopesamanda 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT paychafrederic 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT benalikhadija 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT mikailnidaa 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT soussanmichael 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT lemarigniercharles 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT mechaifrederic 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT nagatsophiele 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT montraversfrancoise 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT deradjiouda 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT durandemmanuel 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT goulenoktiphaine 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT ponscarmediane 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT yenipatrick 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT laouenancedric 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis
AT riouxchristophe 18ffdgpositronemissiontomographyforinitialstagingandhealingassessmentattheendoftherapyinlymphnodesandbonetuberculosis